Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

MAGE-A4-specific TCR gene-transduced T lymphocytes TBI-1201

Autologous human T lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4), with potential immunostimulatory and antineoplastic activities. Upon isolation, transduction, expansion ex vivo, and reintroduction into the patient, MAGE-A4-specific TCR gene-transduced T lymphocytes TBI-1201 binds to tumor cells expressing MAGE-A4. This may result in both an inhibition of growth and increased cell death for MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4 is overexpressed by a variety of cancer cell types.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	TBI-1201

MAGE-A4-specific TCR gene-transduced T lymphocytes TBI-1201

Search NCI's Drug Dictionary